2015 | 2016 | ||||||
Price: | 14.50 | EPS | 0 | 0 | |||
Shares Out. (in M): | 129 | P/E | 0 | 0 | |||
Market Cap (in $M): | 1,871 | P/FCF | 0 | 0 | |||
Net Debt (in $M): | 446 | EBIT | 0 | 0 | |||
TEV (in $M): | 2,317 | TEV/EBIT | 0 | 0 |
Sign up for free guest access to view investment idea with a 45 days delay.
The numbers above and the analysis below are pro forma the Merger with Vistana.
Background: The Vacation Ownership (yes, fka timeshares) industry has four basic pieces:
- VOI Sales and Financing
- Exchange Markets
- Rentals
- Resort Mgmt
The Exhange business is a duopoly with large network effects. WYN has the larger one and II has the smaller one. The VOI Sales business is the most cyclical of the four. Not surprisingly, 2007 was the peak year ($11bn) and 2009 was the trough year ($6bn). Sales have recovered only about a third since 2009. However, due to the new asset-lite model, the cyclicality of the business hits the income statement but does not pose much of a threat to the balance sheet.
There are five (after merger) publicly-traded players in the industry:
- II has largely been an Exchange and a Rentals business. It does have a small Sales and Resort Mgmt business. Vistana will complement it. Vistana is all VOI Sales and Resort Mgmt. The two businesses complement each other as the VOI Sales business feeds customers into the Exchange business. II's lack of captive VOI Sales business has hurt it, and the merger was intended to remedy this problem.
- Wyndam is the big-dog in the industry and does it all. However, note that WYN also has a hotel franchising business that deserves a higher multiple than the vacation ownership pieces.
- DRII is mainly VOI Sales but also has a resort mgmt businss.
- VAC is more balanced between VOI Sales and Resort Mgmt.
- Bluegreen/BFC Financial has been left out of this conversation due to its problems.
The accounting for these businesses is somewhat confusing and obscures the value:
- One key question is how to deal with securitized debt (on balance sheet but non-recourse). If we count the securitized debt in the TEV, we end up adding apples and oranges because the securitized debt has about a 3% interest rate. So we would combine 33x EBITDA contingent claims with 10x EBITDA contingent claims. The consistent way to treat this is to not count the securitized debt towards TEV but to subtract the interest on the securitized debt in calculating EBITDA.
- The cost of VOI sames is a tricky matter due to the Relative Sales Value Method. The problem is that in each period, the cost of sales includes a correction, or true-up, for all past cost of sales. So the cost of sales number can be inconsistent. This is especially true at DRII for some reason. And in one of the oddest accounting legerdemains I have ever seen, DRII simply excludes cost of VOI sales from EBITDA! The SEC directly confronted DRII about this before its IPO, and DRII replied with a formal letter to the SEC, and the SEC bought the explanantion!! Long-story short, DRII's EBITDA numbers are meaningless.
- In this analysis, EBITDA:
- includes all repeated stock comp
- includes all securitization interest but not interest on corp debt
- includes normalized VOI cost of sales
----------------
The market has reacted poorly to the merger of II and Vistana as II stock has gotten socked almost 40% since the announcement. It is cheap on an absolute and relative value basis. I think the market has failed to look past mis-leading headline EBITDA multiples that obscure the value.
The pro-forma cap structure is:
shares: 129mm shrs * $14.50 --> $1,871mm
cash: $101mm
corp debt: $415mm
cash to starwood: $132mm
TEV = $2,381mm. However, and here is the key step, Vistana brings with it $415mm of mortgages, over $200mm of hotel properties, $30mm of unused land, and $240mm of VOI inventory. They can securitize 95% of the mortgages for about 3% ($395mm), develop or sell the land ($30mm), and reduce the inventory ($40mm). This produces $465mm of cash while subtracting $12mm from EBITDA. Finally, the hotels should be valued on a higher metric than the VOI pieces. Subtracting out these pieces gives us Adj TEV of $1,716mm for the VOI business.
Pro-forma EBITDA with cap structure in-line with industry:
II EBITDA: $185mm
Vistana EBITDA: $143mm
less stock comp: ($17mm)
synergies: $21mm
less hotels and interest on sec: ($25mm)
PF EBITDA: $307mm (5.6x)
Less Capex ($25mm) and tax at 30% (Amort Tax Shield) gives us Unlevered FCF of $197mm (8.7x).
Due to the complementing businesses, I think that this merger adds a lot of value to the Exchange piece that is not fully captured in the $21mm, but time will tell. For less than 9x unlevered FCF, we get a high-quality business (the exchange; rentals; mgmt) and a cyclical business (VOI Sales) with a huge ROI that should has demographic tailwinds.
-------
Now for the comps:
WYN is the best comp because it includes an Exchange business, but it deserves a premium multiple both because it includes hotel franchise business and because it is the big-dog, which adds value to its Exchange versus II. With stock at $74.50, the TEV is $11.6bn. The EBITDA is $1.3bn (8.9x), and the unlevered FCF is $770mm (15.1x).
DRII is the next best comp because of its size and relatively small mgmt business. At $27, it has a TEV of $2,061mm (pre the Q4 acquisition). And it has about $270mm EBITDA (7.6x) and the unlevered FCF is $170mm (12.1x).
Finally, VAC at $59.25 has a TEV of $1,580. It has EBITDA of $227mm (7.0x) and unlevered FCF of $145mm (10.9x).
I would argue that the pro-forma II deserves to trade between DRII and WYN due to its pieces . . . I think it deserves 13x unlevered FCF, or $2,565mm . . . which gets us a share price of $21.
I should also note that there has been some insider buying at these levels, and the CEO owns about $12mm of stock. And Liberty will own about 15% of post-merger company.
----------
The risks to the sector are fairly well known: (1) the economy goes south and (2) Airbnb. I'd love to hear others weigh in on whether Airbnb and its ilk are a threat to the larger VOI business.
The risks specific to II are (1) merger falls apart (but this does not seem like much of a risk given price action), (2) the II Exchange fails to keep up pace with RCI (WYN exchange).
They should file the S-4 in the next few days. I believe the S-4 will detail the pro forma numbers with the cap structure in-line with others in the industry. This same situation happened when VAC spun off. Its balance sheet hid significant value.
After that, the next catalyst is the merger (expected Q2 2016) itself and the securitization of the note receivables after the merger.
show sort by |
# | AUTHOR DATE SUBJECT |
---|---|
3 | |
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen’s acquisition of Horizon. As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern District of Illinois, and that Amgen and Horizon will quickly seek the final approvals required under Irish law to close the acquisition. Amgen has consistently stated to the FTC, the courts and the public that it has no reason, ability or intention to bundle Horizon’s TEPEZZA® (teprotumumab-trbw) or KRYSTEXXA® (pegloticase injection) with any of its products. This narrow assurance, formalized in the consent order with the FTC, will have no impact on Amgen’s business. The companies anticipate being able to close the acquisition in early fourth-quarter 2023 and look forward to the opportunity to serve patients around the world suffering from rare diseases.
https://www.businesswire.com/news/home/20230831157622/en/
AMGN prohibited from buying other TED or CRG assets without FTC pre-approval.
| |
2 | |
I recently wrote up Selecta (SELB), which is a small cap Biotech with a moonshot early state pipeline in autoimmune diseases (This is Timothy Springer of MRNA fame's other company) and a late stage product (SEL-212) that just read out a positive Phase III in Chronic Refractory Gout that would compete with HZNP's Krystexxa. SELB has licensed commercial rights to SEL-212 to SOBI but has $630m of regulatory and commercial milestones and a high teens tier royalties on SEL-212 that are expense and tax free. The market is valuing SELB as if SEL-212 will take no market share ($160m market cap, $125m of cash). Skeptics point to Amgen's sales and marketing prowess and probably expect Amgen to use bundling to prevent SEL-212 from taking any Krystexxa market share. We think SEL-212 is a better drug (see my write-up from a couple weeks ago) that will expand the market place. If the HZNP deal is blocked then there will be no bundling, and it seems the best case for AMGN/HZNP that a consent degree against bundling is required to get the deal approved. This should help level the playing field for SELB/SOBI when they enter the market in 2025. I think SELB is a winner anyway, with SEL-212 worth $3-4/share, but it should be a major beneficiary of very scenario except the FTC's lawsuit getting thrown out. But I think it works then anyway. Long SELB should be a consideration for any smaller players who play the HZNP deal.
| |
1 | |
I think you're underestimating the downside here, and it's causing you to overestimate the deal odds. The January 2023 $100 calls last traded for $12.90, which is about their mid as well. Using that option, the market has this at ~78% to close. Just on the merits of the case we've seen and this regimes history of fighting losing cases, I'd probably say HZNP is 90% to win, so it's probably a good bet..... but it's hard for me to bet against the government when they've got just a 20% chance (per the market) and I definitely don't think the market is pricing this at 50/50. |
Are you sure you want to close this position INTERVAL LEISURE GROUP?
By closing position, I’m notifying VIC Members that at today’s market price, I no longer am recommending this position.
Are you sure you want to Flag this idea INTERVAL LEISURE GROUP for removal?
Flagging an idea indicates that the idea does not meet the standards of the club and you believe it should be removed from the site. Once a threshold has been reached the idea will be removed.
You currently do not have message posting privilages, there are 1 way you can get the privilage.
What is wrong with message, "".